LIANG, H.C., M. COSTANZA, N. PRUTSCH, M.W. ZIMMERMAN, E. GURNHOFER, I.A. MONTES-MOJARRO, B.J. ABRAHAM, N. PROKOPH, S. STOIBER, S. TANGERMANN, Cosimo LOBELLO, Jan OPPELT, I. ANAGNOSTOPOULOS, T. HIELSCHER, S. PERVEZ, W. KLAPPER, F. ZAMMARCHI, D.A. SILVA, K.C. GARCIA, D. BAKER, M. JANZ, N. SCHLEUSSNER, F. FEND, Šárka POSPÍŠILOVÁ, A. JANIKOVA, J. WALLWITZ, D. STOIBER, I. SIMONITSCH-KLUPP, L. CERRONI, S. PILERI, L. DE LEVAL, D. SIBON, V. FATACCIOLI, P. GAULARD, C. ASSAF, F. KNORR, C. DAMM-WELK, W. WOESSMANN, Suzanne Dawn TURNER, A.T. LOOK, S. MATHAS, L. KENNER and O. MERKEL. Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma. Nature Communications. London: Nature Publishing Group, vol. 12, No 1, p. 5577-5588. ISSN 2041-1723. doi:10.1038/s41467-021-25379-9. 2021.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma
Authors LIANG, H.C., M. COSTANZA, N. PRUTSCH, M.W. ZIMMERMAN, E. GURNHOFER, I.A. MONTES-MOJARRO, B.J. ABRAHAM, N. PROKOPH, S. STOIBER, S. TANGERMANN, Cosimo LOBELLO (380 Italy, belonging to the institution), Jan OPPELT (203 Czech Republic, belonging to the institution), I. ANAGNOSTOPOULOS, T. HIELSCHER, S. PERVEZ, W. KLAPPER, F. ZAMMARCHI, D.A. SILVA, K.C. GARCIA, D. BAKER, M. JANZ, N. SCHLEUSSNER, F. FEND, Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), A. JANIKOVA, J. WALLWITZ, D. STOIBER, I. SIMONITSCH-KLUPP, L. CERRONI, S. PILERI, L. DE LEVAL, D. SIBON, V. FATACCIOLI, P. GAULARD, C. ASSAF, F. KNORR, C. DAMM-WELK, W. WOESSMANN, Suzanne Dawn TURNER (826 United Kingdom of Great Britain and Northern Ireland, belonging to the institution), A.T. LOOK, S. MATHAS, L. KENNER and O. MERKEL.
Edition Nature Communications, London, Nature Publishing Group, 2021, 2041-1723.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 17.694
RIV identification code RIV/00216224:14740/21:00123350
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1038/s41467-021-25379-9
UT WoS 000700360600032
Keywords in English HODGKIN LYMPHOMANPM-ALKCD30 PROMOTERKINASEANTIBODYTUMORTRANSLOCATIONSINHIBITIONDIAGNOSISIDENTITY
Tags CF GEN, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 9/2/2022 15:29.
Abstract
Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is still unsatisfactory, and already in second line effective treatment options are lacking. To identify genes defining ALCL cell state and dependencies, we here characterize super-enhancer regions by genome-wide H3K27ac ChIP-seq. In addition to known ALCL key regulators, the AP-1-member BATF3 and IL-2 receptor (IL2R)-components are among the top hits. Specific and high-level IL2R expression in ALCL correlates with BATF3 expression. Confirming a regulatory link, IL-2R-expression decreases following BATF3 knockout, and BATF3 is recruited to IL2R regulatory regions. Functionally, IL-2, IL-15 and Neo-2/15, a hyper-stable IL-2/IL-15 mimic, accelerate ALCL growth and activate STAT1, STAT5 and ERK1/2. In line, strong IL-2R alpha-expression in ALCL patients is linked to more aggressive clinical presentation. Finally, an IL-2R alpha-targeting antibody-drug conjugate efficiently kills ALCL cells in vitro and in vivo. Our results highlight the importance of the BATF3/IL-2R-module for ALCL biology and identify IL-2R alpha-targeting as a promising treatment strategy for ALCL.
Links
LM2018132, research and development projectName: Národní centrum lékařské genomiky (Acronym: NCLG)
Investor: Ministry of Education, Youth and Sports of the CR, National Center for Medical Genomics
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
675712, interní kód MUName: ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer (Acronym: ALKATRAS)
Investor: European Union, MSCA Marie Skłodowska-Curie Actions (Excellent Science)
PrintDisplayed: 19/4/2024 08:23